Abstract:Abstract Introduction: Myelodysplastic syndrome (MDS) represents a heterogeneous group of hematopoietic stem cell disorders characterized by single-lineage or multi-lineage cytopenias and a risk of progression to acute myeloid leukemia (AML). Despite the development of new drugs, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potential curative therapy. We have a retrospective analysis of the efficacy and security of the allo-HSCT therapy for MDS in our singal centre. Method: Between June1999 and March 2012, 39 MDS patients with a median age of 32 years (range, 12-52) were transplanted with a matched related donor (n=10), unrelated donor (n=20) or haploidentical donor (n=9) in our centre. Of the patients, 62% were male; 44% had intermediate-1 risk, 13% intermediate-2 risk and 43% poor risk cytogenetics by the International Prognostic Scoring System criteria. The cell source was bone marrow (BM) in 36%, peripheral blood (PB) in 59% and BM+PB in 5%. 51% patients had received chemotherapy prior HSCT. Conditioning regimens were BUCY or BUCY plus ATG for matched related HSCT and unrelated transplants, AraC+BuCy+ATG+MeCCNU for haploidentical transplants. The median number of CD34+ cells/kg infusion was 5.52×106(range, 0.8×106-10.38×106).Graft-versus-host disease prophylaxis was employed by cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate (MTX). 25 patients received serum ferritin measurement berore HSCT. The mediun level of serum ferritin was 1100ng/ml (range, 456-2318). Result: The median follow-up was 27 months(range,1.5-154). The 3-year disease free survival(DFS) was 60.8%. Transplant related mortality(TRM) was assessed at 37% on the whole cohort. 5% has no engraftment for a total of 2 patients. A neutrophil count of >0.5 × 109/L was achieved at a median of 12 days (range, 9–24 days) and a platelet count of >20 × 109/L within 14 days (9–49 days) post-transplant. Acute GVDH grade 1-2 was documented in 49%, grade 3-4 in 5% and no GVDH in 46%. Chronic GVHD could be identified in 27 patients (69%), 5 of whom had extensive disease, while the other 22 had limited disease. Overall 14 patients (36%) died. Causes of death were Infection 57%,GVDH 8%, haemorrhage 14%, engraft failure 14% and “other causes” 7%. Only one patients died because of relapse of the disease.DFS according to donor source (matched related donor 87.5%, unrelated donor 51.6% and haploidentical donor 55.6%) was not significant (p =0.22 ). Likewise no significant difference was found on DFS among BM 57%, PB 66.4% and BM+PB 50% (p =0.65). A similar DFS was seen in different risk categories (56.7% in intermediate, 66.7% in high-risk; p=0.51). No difference was seen in DFS according to the CD34+ cell number and whether received chemotherapy prior to HSCT. Only the elevated serum ferritin is associated with inferior DFS after HSCT(p =0.018 ). Disclosures No relevant conflicts of interest to declare.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis

Serem Ferritin Was the Only Prognostic Factor for Disease Free Survival in Mds Patients after Allo-Hsct: A Single Centre Study

Dysfunctional Bone Marrow Mesenchymal Stem Cells in Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

An Unbalanced Monocyte Macrophage Polarization In The Bone Marrow Microenvironment Of Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation.

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation

[Clinical outcomes of allogeneic hematopoietic stem cell transplantation from matched sibling donor for myelofibrosis]

Myelofibrosis and allogeneic transplantation: critical points and challenges

2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature

Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis

The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation

[Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for 10 Patients with Myelofibrosis].

When and how to transplant in myelofibrosis – recent trends

The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia

Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights☆

[Selected donor CD34(+) cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report]

Minimal Residual Disease Status At Day+100 Post Allogeneic Hematopoietic Stem Cell Transplantation Is A Powerful Predictor For Post-Transplant Outcome In Patients With High Risk Acute Leukemia

Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation

Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]